BioCentury
ARTICLE | Product Development

eGenesis $125M C round to support clinical trials of kidney, islet transplants from engineered pigs

CEO Sekhri says goal is to ‘eliminate the waiting list’ for organ transplants

March 3, 2021 2:21 AM UTC
Updated on Mar 3, 2021 at 3:12 PM UTC

eGenesis plans to bring its lead CRISPR-edited pig-to-human kidney and pancreatic islet transplant programs into the clinic and scale GMP production with its untranched $125 million series C financing. 

Given the high unmet need for organ transplants, President and CEO Paul Sekhri said the company’s near-term goal is to “create a kind of unlimited supply of allo-looking human-compatible organs to eliminate the waiting list.” Recipients would still require immunosuppression. ...

BCIQ Company Profiles

eGenesis Inc.